Azithromycine - Only for Children Pharmaceuticals
Latest Information Update: 23 Dec 2021
Price :
$50 *
At a glance
- Originator Only for Children Pharmaceuticals
- Class Anti-inflammatories; Antibacterials; Antivirals; Eye disorder therapies; Macrolides; Small molecules
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bronchopulmonary dysplasia
Most Recent Events
- 28 May 2019 No recent reports of development identified for clinical-Phase-Unknown development in Bronchopulmonary-dysplasia(In infants) in Unknown (IV, Infusion)
- 09 May 2016 Chemical structure information added
- 29 Apr 2016 Clinical trials in Bronchopulmonary dysplasia (IV) before April 2016